Published pharmacoeconomic analyses: Science or marketing?

Internal Medicine Journal

Volumn 33, Issue 9-10, 2003, Pages 403-404

  Henry, D ^a   Lang, D ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG USE; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PUBLICATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; HUMANS; MARKETING; PUBLISHING; RAMIPRIL;

EID: 0142074372     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00473.x     Document Type: Editorial

References (10)

1. Smith MG, Neville M, Middleton J. Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study. Intern Med J 2003; 33: 414-419.
2. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: A review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283: 2116-21.
3. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282: 1453-7.
4. Kassirer JP, Angell M. The Journal's policy on cost-effectiveness analysis. N Engl J Med 1994; 331: 669-70.
5. Rennie D, Luft HS. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000; 283: 2158-60.
6. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Affairs 2001; 20: 104-14.
7. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
8. McAlister FA, Laupacis A, Well GA, Sackett DL. Users' guides to the medical literature XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999; 282: 1371-7.
9. Skolnick AA. Drug firm suit fails to halt production of Canadian health technology report. JAMA 1998; 280: 683-4.
10. Shuchman M. Drug company threatens legal action over Canadian guidelines. Br Med J 1999; 319: 1388.